Michelle Auld
Family Health · Hot Springs, ARNPI 1336699941
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 29.9% of the total.
Across 201 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$602
- Abbott$306
- GSK$256
- Pfizer$254
- AstraZeneca$253
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,128100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $1,233 |
| Otsuka America Pharmaceutical, Inc. | 15 | $602 |
| Abbott | 19 | $306 |
| GSK | 11 | $256 |
| Pfizer | 10 | $254 |
| AstraZeneca | 9 | $253 |
| Amgen(2 entities) | 8 | $193 |
| Merz North America, Inc. | 1 | $128 |
| Antares Pharma, Inc. | 8 | $127 |
| Galderma Laboratories, L.p. | 2 | $125 |
| Astellas Pharma US Inc | 6 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Bayer | 3 | $56 |
| Johnson & Johnson | 3 | $51 |
| Lilly USA, LLC | 2 | $26 |
| Novo Nordisk | 2 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $24 |
| The Binding Site Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Corium, LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few family health providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $42,375 |
| MounjaroTirzepatide | 41 | $41,657 |
| TrulicityDulaglutide | 24 | $21,146 |
| VraylarCariprazine Hcl | 11 | $15,737 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $12,017 |
| FarxigaDapagliflozin Propanediol | 15 | $8,697 |
| BelsomraSuvorexant | 19 | $8,359 |
| LinzessLinaclotide | 11 | $6,459 |
| Duloxetine Hcl | 55 | $4,225 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,795 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 12 | $2,647 |
| Gabapentin | 106 | $1,620 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,224 |
| Omeprazole | 100 | $1,170 |
| Pregabalin | 21 | $1,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $26 | $62,80365 claims |
| Novo NordiskOzempic | $25 | $42,37539 claims |
| AbbVieVraylar, Linzess | $1,233 | $22,19622 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $253 | $20,71427 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $33747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Arkansason file to place this against a meaningful peer group, so we don't.
Other family health in Hot Springs
- Linda DukesHot Springs$7K
- Jennifer JonesHot Springs$4K
- Sherry McCraryWynne$1K
- Madison BirdnoJonesboro$836
- Marie Pham-RussellFort Smith$380
- Mirenda MartinSalem$48
- Holly TolhurstJacksonville$45
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.